Claims for Patent: 7,214,532

Summary for Patent: 7,214,532

Title:	Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof
Abstract:	The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.
Inventor(s):	Stern; Anne (Penzberg, DE), Brandt; Michael (Iffeldorf, DE), Honold; Konrad (Penzberg, DE), Auer; Johannes (Penzberg, DE), Koll; Hans (Weilheim, DE), Franze; Reinhard (Penzberg, DE), Pessara; Ulrich (Weilheim, DE)
Assignee:	Roche Diagnostics, GmbH (Mannheim, DE)
Application Number:	10/351,397
Patent Claims:	1. A DNA construct useful in homologous recombination, comprising: (i) a pair of flanking DNA sequences which are homologous to regions of the human gene which encodes erythropoietin, said regions being selected from the group consisting of 5'-untranslated sequences, a modified portion of exon 1, and intron 1, to permit homologous recombination, said modified portion of exon 1 corresponding to the first four codons of the signal sequence coding region, and coding for a sequence of four amino acids of formula Met Xaa Xaa Xaa (SEQ ID NO: 5) wherein the first Xaa is Gly or Ser, the second Xaa is Ala, Val, Leu, Ile, Ser or Pro, and the third Xaa is Pro, Arg, Cys or His, with the proviso that said four amino acid sequence is not Met Gly Val His (SEQ ID NO: 6). (ii) a gene which codes for a positive selection marker, and (iii) a heterologous expression control sequence which comprises a promoter. 2. The DNA construct of claim 1, wherein Met Xaa Xaa Xaa is TABLE-US-00007 (a) Met-Gly-Ala-His (SEQ ID NO:7) (b) Met-Ser-Ala-His (SEQ ID NO:8) (c) Met-Gly-Val-Pro (SEQ ID NO:9) or (d) Met-Ser-Val-His (SEQ ID NO:10). 3. The DNA construct of claim 1, further comprising an amplifiable gene. 4. Plasmid p189 (DSM 11661). 5. The DNA construct of claim 1 comprising a translation start site, wherein the heterologous expression control sequence is positioned within 1100 nucleotides of the translation start site.

Details for Patent 7,214,532

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-23